A 9-year-old neutered male Boxer presents with a cough, i...

Thank you for reaching out regarding this Boxer. This is a concerning presentation, and we need to act decisively.

Based on the clinical signs you've described—cough and developing ascites—this patient is actually experiencing Stage C dilated cardiomyopathy, not Stage B2.

Here's why this distinction is critical:

* Stage B2 refers to structural heart disease (like the LV dilation and severely decreased contractility you've identified) with significant remodeling, but without any current or historical clinical signs of congestive heart failure (CHF).
* The presence of cough (which, in a large breed dog with DCM, is often a sign of pulmonary edema) and ascites (indicating right-sided heart failure) definitively places this patient in Stage C, as these are overt clinical signs of CHF.

Initiation of Pimobendan:

Pimobendan is absolutely indicated for this patient, and in fact, should be initiated immediately.

For Stage B2 DCM: In Doberman Pinschers with occult (Stage B2) DCM, the PROTECT study demonstrated that pimobendan significantly delays the onset of clinical signs of CHF. While not specifically studied for all breeds with occult DCM, the principle of delaying progression is often extrapolated.

For Stage C DCM (as in your patient): Pimobendan is a cornerstone of therapy for dogs in active CHF, regardless of the underlying cause. It provides positive inotropic support (improving contractility) and vasodilation (reducing preload and afterload), which together improve cardiac output and alleviate CHF signs.

Treatment Recommendations for Stage C DCM:

Given the active signs of CHF (cough, ascites), we need to implement a full multi-drug protocol. This patient requires:

Pimobendan:

* Dog dose: 0.25-0.3 mg/kg PO Every 12 hours.
Important Note: Pimobendan must* be given on an empty stomach (at least one hour before food) as food significantly reduces its absorption.

Furosemide: To manage the pulmonary edema and ascites.

* Acute CHF dog dose: For initial stabilization, you might consider 2-4 mg/kg IV bolus, then 1-2 mg/kg IV q2-4h or a CRI until respiratory rate normalizes.
* Chronic CHF dog dose: Once stable, transition to 1-4 mg/kg PO q8-12h. Titrate to the lowest effective dose based on resolution of clinical signs and sleeping respiratory rate.
* Monitoring: Monitor renal values (BUN/creatinine) and electrolytes (especially potassium) closely. Mild azotemia is often an acceptable trade-off for CHF control.

ACE Inhibitor (e.g., Enalapril or Benazepril):

* Dog dose (Enalapril): 0.5 mg/kg PO Every 12-24 hours.
* Monitoring: Recheck renal values and blood pressure 5-7 days after initiation, then every 3-6 months. A mild increase in BUN/creatinine (up to 30%) is often tolerated.

Spironolactone: This is a weak diuretic and aldosterone antagonist, which has beneficial anti-fibrotic and anti-remodeling effects. The DELAY study showed a survival benefit when added to standard CHF therapy.

* Dog dose: 1-2 mg/kg PO Every 12-24 hours.
* Monitoring: Monitor electrolytes, particularly potassium, especially when combined with an ACE inhibitor.

Summary:

This Boxer is in Stage C DCM and requires immediate initiation of pimobendan, furosemide, an ACE inhibitor, and spironolactone. The prompt recognition of clinical signs and appropriate staging is crucial for effective management and improving the patient's quality of life. Please ensure the owner is tracking sleeping respiratory rate daily, as this will be your most valuable tool for monitoring response to therapy and detecting early signs of decompensation.

Let me know if you have any questions as you initiate this therapy, and I'd be happy to discuss further.